Jardiance similar drugs
Pro Research Analysisby 
Searched over 200M research papers
Jardiance and Similar Drugs: A Comprehensive Overview
Introduction to Jardiance (Empagliflozin)
Empagliflozin, marketed under the brand name Jardiance, is a sodium-glucose cotransporter-2 (SGLT2) inhibitor used primarily for the treatment of type 2 diabetes mellitus (T2DM). It works by inhibiting glucose reabsorption in the kidneys, promoting glucosuria, and thereby reducing blood glucose levels . Jardiance is known for its once-daily oral administration and has shown additional benefits such as weight loss and blood pressure reduction .
Pharmacokinetics and Bioequivalence
Studies have demonstrated the pharmacokinetic properties and safety of empagliflozin. For instance, a study conducted on healthy Chinese subjects confirmed the bioequivalence of a test formulation of empagliflozin with the brand-name drug Jardiance under both fasting and fed conditions. Another study assessed the bioequivalence between Izaban® and Jardiance® in healthy adults, confirming that both formulations are bioequivalent based on pharmacokinetic parameters.
Efficacy and Safety in Type 2 Diabetes
Empagliflozin has been extensively studied for its efficacy in managing T2DM. It has shown significant reductions in glycated hemoglobin (HbA1c), fasting, and postprandial glucose levels. Additionally, it has demonstrated cardioprotective and renoprotective effects, particularly in patients with established cardiovascular disease . Unlike some other SGLT2 inhibitors, empagliflozin has not been associated with an increased risk of amputation or bone fractures.
Cardiovascular and Renal Benefits
The EMPA-REG OUTCOME trial highlighted the cardiovascular benefits of empagliflozin, showing a reduction in the risk of cardiovascular death and hospitalization for heart failure . Similarly, the EMPEROR-Reduced study found that empagliflozin significantly lowered the risk of hospitalization in patients with heart failure with reduced ejection fraction.
Use in Pediatric and Special Populations
Empagliflozin has also been approved for use in children aged 10 years and older, expanding its utility beyond adult patients. This approval underscores its safety and efficacy across different age groups.
Comparison with Other SGLT2 Inhibitors
Empagliflozin is one of several SGLT2 inhibitors recommended by the National Institute for Health and Care Excellence (NICE) for adults with T2DM, alongside canagliflozin (Invokana) and dapagliflozin (Forxiga). These drugs are particularly recommended when metformin, sulfonylurea, or pioglitazone are contraindicated or not tolerated.
Potential Dual Benefits in Neurological Disorders
Emerging research suggests that empagliflozin and other antidiabetic drugs may also act as dual inhibitors against acetylcholinesterase and beta-secretase, enzymes implicated in Alzheimer's disease. This dual action could potentially offer therapeutic benefits for diabetes-associated neurological disorders.
Conclusion
Empagliflozin (Jardiance) stands out as a highly effective and well-tolerated treatment for type 2 diabetes, with additional benefits for cardiovascular and renal health. Its approval for pediatric use and potential dual benefits in neurological disorders further enhance its therapeutic profile. As part of the SGLT2 inhibitor class, it offers a valuable option for patients, particularly those at high cardiovascular risk or those who cannot tolerate other antidiabetic medications.
Sources and full results
Most relevant research papers on this topic